is predicted to increase the exposure to didanosine.
▶ Leflunomide is predicted to increase the exposure to
ganciclovir.oTheoretical → Also see TABLE 15 p. 1378
▶ Mycophenolate is predicted to increase the risk of
haematological toxicity when given with
ganciclovir.o ▶ Teriflunomide is predicted to increase the exposure to
Gefitinib → see TABLE 15 p. 1378 (myelosuppression)
▶ Antacids are predicted to slightly decrease the exposure to
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to gefitinib.oTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to
gefitinib.o ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to gefitinib.oStudy
is predicted to increase the exposure to gefitinib.
▶ Bosentan is predicted to decrease the exposure to gefitinib.
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to gefitinib.oTheoretical
is predicted to increase the exposure to gefitinib.
▶ Gefitinib is predicted to increase the anticoagulant effect of
is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Efavirenz is predicted to decrease the exposure to gefitinib.
▶ Enzalutamide is predicted to decrease the exposure to
▶ H2 receptor antagonists are predicted to slightly to moderately
decrease the exposure to gefitinib.oStudy
▶ HIV-protease inhibitors are predicted to increase the exposure
is predicted to increase the exposure to gefitinib.
Study → Also see TABLE 15 p. 1378
is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Macrolides (clarithromycin) are predicted to increase the
▶ Macrolides (erythromycin) are predicted to increase the
exposure to gefitinib.oTheoretical
▶ Mitotane is predicted to decrease the exposure to gefitinib.
Avoid.rStudy → Also see TABLE 15 p. 1378
is predicted to increase the exposure to gefitinib.
▶ Nevirapine is predicted to decrease the exposure to gefitinib.
is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Gefitinib is predicted to increase the risk of bleeding events
when given with phenindione.rTheoretical
▶ Proton pump inhibitors are predicted to decrease the exposure
▶ Rifampicin is predicted to decrease the exposure to gefitinib.
▶ St John’s Wort is predicted to decrease the exposure to
Gemcitabine → see TABLE 15 p. 1378 (myelosuppression)
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
gemcitabine. Public Health England advises avoid (refer to
Gentamicin → see aminoglycosides
▶ Antiarrhythmics (dronedarone) potentially increase the
exposure to glecaprevir.oTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to moderately decrease
the exposure to glecaprevir. Avoid.rStudy
▶ Antiepileptics (eslicarbazepine, oxcarbazepine) potentially
decrease the exposure to glecaprevir. Avoid.rTheoretical
▶ Antifungals, azoles (itraconazole, ketoconazole) potentially
increase the exposure to glecaprevir.oTheoretical
▶ Bosentan is predicted to decrease the exposure to glecaprevir.
▶ Ciclosporin increases the exposure to glecaprevir. Avoid or
potentially increases the exposure to glecaprevir.
▶ Combined hormonal contraceptives (containing
ethinylestradiol) are predicted to increase the risk of
increased ALT concentrations when given with glecaprevir.
▶ Crizotinib potentially decreases the exposure to glecaprevir.
▶ Glecaprevir (with pibrentasvir) increases the exposure to
▶ Glecaprevir (with pibrentasvir) increases the exposure to
▶ Efavirenz is predicted to decrease the exposure to glecaprevir.
▶ Enzalutamide is predicted to greatly decrease the
concentration of glecaprevir. Avoid.rStudy
▶ HIV-protease inhibitors (atazanavir, darunavir, lopinavir)
(boosted with ritonavir) increase the exposure to glecaprevir.
▶ HIV-protease inhibitors (ritonavir) increase the exposure to
▶ Lumacaftor potentially decreases the exposure to glecaprevir.
▶ Mitotane is predicted to greatly decrease the concentration of
▶ Nevirapine is predicted to decrease the exposure to
▶ Rifampicin markedly affects the exposure to glecaprevir.
▶ St John’s Wort is predicted to decrease the exposure to
▶ Glecaprevir (with pibrentasvir) markedly increases the
exposure to statins (atorvastatin). Avoid.rStudy
▶ Glecaprevir (with pibrentasvir) is predicted to increase the
exposure to statins (fluvastatin).oTheoretical
▶ Glecaprevir (with pibrentasvir) increases the exposure to
statins (pravastatin). Use with caution and adjust pravastatin
▶ Glecaprevir (with pibrentasvir) increases the exposure to
statins (rosuvastatin). Use with caution and adjust rosuvastatin
▶ Glecaprevir (with pibrentasvir) increases the exposure to
statins (simvastatin). Avoid.oStudy
BNF 78 Frovatriptan — Glecaprevir 1459
▶ Glecaprevir (with pibrentasvir) slightly increases the exposure
to tacrolimus. Monitor and adjust dose.nStudy
Glibenclamide → see sulfonylureas
Gliclazide → see sulfonylureas
Glimepiride → see sulfonylureas
▶ Glucagon increases the anticoagulant effect of coumarins
▶ Glucosamine potentially decreases the anticoagulant effect of
coumarins (acenocoumarol).oAnecdotal
▶ Glucosamine potentially increases the anticoagulant effect of
coumarins (warfarin). Avoid.oAnecdotal
▶ Antiepileptics (valproate) potentially oppose the effects of
glycerol phenylbutyrate.oTheoretical
▶ Corticosteroids potentially oppose the effects of glycerol
▶ Haloperidol potentially opposes the effects of glycerol
Glyceryl trinitrate → see nitrates
Glycopyrronium → see TABLE 10 p. 1377 (antimuscarinics)
ROUTE-SPECIFIC INFORMATION Since systemic absorption can
follow topical application, the possibility of interactions
Golimumab → see monoclonal antibodies
Granisetron → see TABLE 9 p. 1377 (QT-interval prolongation), TABLE 13
▶ Dopamine receptor agonists (apomorphine) are predicted to
increase the risk of severe hypotension when given with
▶ Grapefruit juice is predicted to increase the exposure to
abemaciclib. Avoid.oTheoretical
▶ Grapefruit juice moderately decreases the exposure to
▶ Grapefruit juice increases the exposure to antiarrhythmics
▶ Grapefruit juice moderately increases the exposure to
antiarrhythmics (dronedarone). Avoid.rStudy
▶ Grapefruit juice increases the exposure to antiarrhythmics
(propafenone). Monitor and adjust dose.oStudy
▶ Grapefruit juice slightly increases the exposure to antiepileptics
(carbamazepine). Monitor and adjust dose.oStudy
▶ Grapefruit juice slightly decreases the exposure to
antihistamines, non-sedating (bilastine). Bilastine should be
taken 1 hour before or 2 hours after
▶ Grapefruit juice increases the exposure to antimalarials
▶ Grapefruit juice is predicted to increase the concentration of
antimalarials (piperaquine). Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice greatly decreases the exposure to beta blockers,
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the concentration of
▶ Grapefruit juice increases the exposure to buspirone. Avoid.
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice very slightly increases the exposure to calcium
channel blockers (amlodipine). Avoid.nStudy
▶ Grapefruit juice increases the exposure to calcium channel
blockers (felodipine). Avoid.oStudy
▶ Grapefruit juice is predicted to increase the exposure to calcium
channel blockers (lercanidipine). Avoid.oTheoretical
▶ Grapefruit juice increases the exposure to calcium channel
▶ Grapefruit juice increases the exposure to calcium channel
blockers (nifedipine, verapamil). Avoid.nStudy
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice increases the concentration of ciclosporin.
▶ Grapefruit juice markedly decreases the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
cobimetinib. Avoid.rTheoretical
▶ Grapefruit juice moderately increases the exposure to oral
corticosteroids (budesonide). Avoid.oStudy
▶ Grapefruit juice is predicted to increase the exposure to
crizotinib. Avoid.oTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
eliglustat. Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
everolimus. Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
guanfacine. Avoid.oTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
. Separate administration by 12 hours.o ▶ Grapefruit juice is predicted to increase the exposure to
lurasidone. Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
palbociclib. Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors
increases the exposure to pimozide. Avoid.
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
quetiapine. Avoid.rTheoretical
▶ Grapefruit juice is predicted to increase the concentration of
ranolazine. Avoid.rTheoretical
1460 Glecaprevir — Grapefruit juice BNF 78
▶ Grapefruit juice is predicted to increase the exposure to
regorafenib. Avoid.oTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
ribociclib. Avoid.oTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice increases the concentration of sirolimus.
▶ Grapefruit juice moderately increases the exposure to SSRIs
▶ Grapefruit juice increases the exposure to statins (atorvastatin).
▶ Grapefruit juice increases the exposure to statins (simvastatin).
▶ Grapefruit juice is predicted to increase the exposure to
▶ Grapefruit juice greatly increases the concentration of
▶ Grapefruit juice is predicted to increase the concentration of
temsirolimus. Use with caution or avoid.oTheoretical
▶ Grapefruit juice is predicted to increase the exposure to
No comments:
Post a Comment
اكتب تعليق حول الموضوع